TY - JOUR
T1 - Olanzapine in Huntington's disease
AU - Paleacu, D.
AU - Anca, M.
AU - Giladi, N.
PY - 2002/6
Y1 - 2002/6
N2 - Objectives - To study the effect of olanzapine (OL) in Huntington's disease (HD) patients. Design and methods - Eleven HD patients (five men), aged 47.6 ± 11.4 years and with disease duration of 11.2 ± 3.3 years received OL. Assessment was carried out using the Clinical Global Impression of Change Scale (CGIC) and the Unified Huntington's Disease Rating Scale behavioral (UHDRS - b) and motor (UHDRS - m) at 6 month intervals. Results - Nine patients were treated for 9.8 ± 5.9 months. The mean OL dose/patient was 11.4 ± 8.5 mg/day (median 10 mg/day). Mean CGIC was 2.1 ± 0.8. UHDRS - b improved significantly (P < 0.0001) and UHDRS - m did not change. Chorea improved in five patients and two dropped out because of drug eruption and lack of efficacy. Conclusion - OL is a good alternative treatment in HD, mainly for the psychiatric symptoms and moderately effective for the motor symptoms, possibly because of its effect on chorea. We suggest OL should be used in HD patients with the adult onset form, severe chorea and/or severe psychiatric disturbances.
AB - Objectives - To study the effect of olanzapine (OL) in Huntington's disease (HD) patients. Design and methods - Eleven HD patients (five men), aged 47.6 ± 11.4 years and with disease duration of 11.2 ± 3.3 years received OL. Assessment was carried out using the Clinical Global Impression of Change Scale (CGIC) and the Unified Huntington's Disease Rating Scale behavioral (UHDRS - b) and motor (UHDRS - m) at 6 month intervals. Results - Nine patients were treated for 9.8 ± 5.9 months. The mean OL dose/patient was 11.4 ± 8.5 mg/day (median 10 mg/day). Mean CGIC was 2.1 ± 0.8. UHDRS - b improved significantly (P < 0.0001) and UHDRS - m did not change. Chorea improved in five patients and two dropped out because of drug eruption and lack of efficacy. Conclusion - OL is a good alternative treatment in HD, mainly for the psychiatric symptoms and moderately effective for the motor symptoms, possibly because of its effect on chorea. We suggest OL should be used in HD patients with the adult onset form, severe chorea and/or severe psychiatric disturbances.
KW - Huntington's disease
KW - Olanzapine
KW - Treatment
UR - https://www.scopus.com/pages/publications/0036276160
U2 - 10.1034/j.1600-0404.2002.01197.x
DO - 10.1034/j.1600-0404.2002.01197.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12027832
AN - SCOPUS:0036276160
SN - 0001-6314
VL - 105
SP - 441
EP - 444
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
IS - 6
ER -